EXPERIMENTAL IMMUNOLOGY
Fenofibrate treatment of rats with experimental autoimmune myocarditis by alleviating Treg/Th17 disorder
Submission date: 2015-04-16
Final revision date: 2015-12-26
Acceptance date: 2015-12-29
Publication date: 2016-03-24
Cent Eur J Immunol 2016;41(1):64-70
KEYWORDS
ABSTRACT
Objective: To investigate the curative effect of fenofibrate on rats with experimental autoimmune myocarditis (EAM) and its immunological mechanism.
Material and methods: Twenty-four rats were equally randomised into three groups: an EAM group, fenofibrate group, and control group, then a subcutaneous injection of purified pig cardiac myosin was given to the EAM group rats and the fenofibrate group, while equivalent normal saline (NS) was given to the control group. After that, the fenofibrate group received fenofibrate by gavage (100 mg/kg/d) and equivalent NS was given to the other groups, lasting for 17 days. Then the rats were sacrificed in order to take heart tissues; HE staining and qRT-PCR method was used to assess the severity of heart failure and mRNA level of cytokines; NK-B protein content was analyzed by Western-blot. Healthy rat spleen tissue was prepared for splenocyte suspension. Subsequently, splenocytes were administrated similarly to the test in vivo for detecting cytokine mRNA levels.
Results: Compared with the control group, heart weight in EAM group was heavier than in the other groups (p < 0.05), and there was severe inflammatory cell infiltration in heart tissue of the EAM group. Th17 cell-related cytokines mRNA levels in the EAM group/induction group were evidently higher than in other groups (p < 0.05); FOX-p3 mRNA level in the EAM group/induction group was lower than other groups, mRNA levels of IL-10 and FOX-p3 in the fenofibrate group were higher than in the EAM group/induction group (p < 0.05). Fenofibrate could significantly inhibit the up-regulation of NF-B protein in EAM rats (p < 0.05).
Conclusions: By inhibiting the development of Th17 cells and promoting the differentiation of Tregs, fenofibrate alleviated Treg/Th17 disorder and inhibited inflammation in rats with EAM, thus improving the prognosis.
Material and methods: Twenty-four rats were equally randomised into three groups: an EAM group, fenofibrate group, and control group, then a subcutaneous injection of purified pig cardiac myosin was given to the EAM group rats and the fenofibrate group, while equivalent normal saline (NS) was given to the control group. After that, the fenofibrate group received fenofibrate by gavage (100 mg/kg/d) and equivalent NS was given to the other groups, lasting for 17 days. Then the rats were sacrificed in order to take heart tissues; HE staining and qRT-PCR method was used to assess the severity of heart failure and mRNA level of cytokines; NK-B protein content was analyzed by Western-blot. Healthy rat spleen tissue was prepared for splenocyte suspension. Subsequently, splenocytes were administrated similarly to the test in vivo for detecting cytokine mRNA levels.
Results: Compared with the control group, heart weight in EAM group was heavier than in the other groups (p < 0.05), and there was severe inflammatory cell infiltration in heart tissue of the EAM group. Th17 cell-related cytokines mRNA levels in the EAM group/induction group were evidently higher than in other groups (p < 0.05); FOX-p3 mRNA level in the EAM group/induction group was lower than other groups, mRNA levels of IL-10 and FOX-p3 in the fenofibrate group were higher than in the EAM group/induction group (p < 0.05). Fenofibrate could significantly inhibit the up-regulation of NF-B protein in EAM rats (p < 0.05).
Conclusions: By inhibiting the development of Th17 cells and promoting the differentiation of Tregs, fenofibrate alleviated Treg/Th17 disorder and inhibited inflammation in rats with EAM, thus improving the prognosis.
REFERENCES (23)
1.
Cihakova D, Rose NR (2008): Pathogenesis of myocarditis and dilated cardiomyopathy. Adv Immunol 99: 95-114.
2.
Park H, Li Z, Yang XO, et al. (2005): A distinct lieage of CD4+ T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6: 1133-1141.
3.
Joosten LA, Abdollahi-Roodsaz S, Heuvelmans-Jacobs M, et al. (2008): T cell dependence of chronic destructive murine arthritis induced by repeated local activation of Toll-like receptor-driven pathways: crucial role of both interleukin-1 beta and interleukin-17. Arthritis Rheum 58: 98-108.
4.
Yang J, Chu Y, Yang X, et al. (2009): Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum 60: 1472-1483.
5.
El-Behi M, Ciric B, Dai H, et al. (2011): The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat Immunol 12: 568-575.
6.
Codarri L, Gyülvészi G, Tosevski V, et al. (2011): RORt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol 12: 560-567.
7.
Shiomi A, Usui T (2015): Privotal roles of GM-CSF in autoimmunity and inflammation. Mediators Inflamm 2015: 568543.
8.
Planavila A, Iglesias R, Giralt M, Villarroya F (2011): Sirt1 acts in association with PPAR to protect the heart from hypertrophy, metabolic dysregulation, and inflammation. Cardiovasc Res 90: 276-284.
9.
Diep QN, Benkirane K, Amiri F, Cohn JS, Endemann D, Schiffrin EL (2004): PPARalpha activator fenofibrate inhibits myocardial inflammation and fibrosis in antiotensin II-infused rats. J Mol Cell Cardiol 36: 295-304.
10.
Yuan J, Wu J, Han ZG (2008): Fenofibrate improves energy metabolism and attenuates isoproterenol induced acute myocardial ischemic injury in rats via PPAR alpha activation. Zhonghua Xin Xue Guan Bing Za Zhi 36: 847-850.
11.
Kamata S, Miyagawa S, Fukushima S, et al. (2014): Targeted delivery of adipocytokines into the heart by induced adipocyte cell-sheet transplantation yields immune tolerance and functional recovery in autoimmune-associated myocarditis in rats. Circ J 79: 169-179.
12.
Hasan M, Neumann B, Haupeltshofer S, et al. (2015): Activation of TGF--induced non-Smad signaling pathways during Th17 differentiation. Immunol Cell Biol 93: 662-672.
13.
Bettelli E, Carrier Y, Gao W, et al. (2006): Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235-238.
14.
Balakumar P, Rohilla A, Mahadevan N (2011): Pleiotropic actions of fenofibrate on the heart. Pharmacol Res 63: 8-12.
15.
Ivaov II, Zhou L, Littman DR (2007): Transcriptional regulation of Th17 cell differentiation. Semin Immunol 9: 409-417.
16.
Zhou L, Ivanov II, Spolski R, et al. (2007): IL-26 programs T(H) 217 cell differentiation by promoting sequential engagement of the IL221 and IL223 pathways. Nat Immunol 8: 967-974.
17.
Chen W, Jin W, Hardegen N, et al. (2003): Conversion of peripheral CD4+CD25- naïve T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198: 1875-1886.
18.
Zhang F, Meng G, Strober W (2008): Ineractions among the transcription factors Runx1, RORgammat and Foxp3 regulate the differentiation of interleukin 17-producing T cells. Nat Immunol 9: 1297-1306.
19.
Zhou Z, Sun W, Liang Y, et al. (2012): Fenofibrate inhibrated the differentiation of T helper 17 cells in vitro. PPAR Res 2012: 145654.
20.
Jeon Y, Jung Y, Kim MC, et al. (2014): Sargahydroquinoic acid inhibits TNF-induced AP-1 and NF-B signaling in HaCaT cells through PPAR activation. Biochem Biophys Res Commun 450: 1553-1559.
21.
Wang W, Lin Q, Lin R, et al. (2013): PPAR agonist fenofibrate attenuates TNF--induced CD40 expression in 3T3-L1 adipocytes via the SIRT1-dependent signaling pathway. Exp Cell Res 319: 1523-1533.
22.
Acuff NV, Li X, Kirkland R, Nagy T, Watford WT (2015): Tumor Progression Locus 2 Differentially Regulates IFN and IL-17 Production by Effector CD4+ T Cells in a T Cell Transfer Model of Colitis. PLoS One 10: e0119885.
23.
Abe M, Hiasa Y, Onji M (2013): T helper 17 cells in autoimmune liver diseases. Clin Dev Immunol 2013; 2013: 607073.
Share
RELATED ARTICLE
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
